New POC allergy test has been cleared by FDA
The US medical agency FDA has granted Phadia the clearance to sell and market its new POC allergy test ImmunoCAP® Rapid product in US.
“This is a historical event in the diagnostic industry since it is the first semi-quantitative POC allergy test that has been FDA cleared. It is a major milestone for Phadia in building the ImmunoCAP franchise even stronger and will provide more patients with allergy-like symptoms the possibility to get a correct diagnosis” says Håkan Englund, Executive Vice President Phadia AB.
ImmunoCAP Rapid will be introduced on the US market later in the year. The European version of ImmunoCAP Rapid has been marketed and sold in selected European countries for over 2 years.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.